Radiology of Castleman disease: the pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity

被引:9
作者
Din, F. [1 ]
Mellor, F. [1 ]
Millard, T. [1 ]
Pace, E. [1 ]
Khan, N. [1 ]
Attygalle, A. D. [2 ]
Cunningham, D. [2 ]
Zafar, S. [1 ]
Sharma, B. [1 ]
机构
[1] Royal Marsden NHS Trust, Dept Radiol, 203 Fulham Rd, London SW3 6JJ, England
[2] Royal Marsden NHS Trust, Lymphoma Unit, London, England
关键词
NON-HODGKIN-LYMPHOMA; SPECTRUM; CT; CRITERIA; UPDATE;
D O I
10.1016/j.crad.2022.01.045
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Castleman Disease (CD) is a rare entity that typically presents as an enhancing nodal mass in the mediastinum or head and neck region on computed tomography (CT). It may manifest as unicentric or multicentric regions of lymph node enlargement. A key clinical issue in the context of CD is delayed diagnosis, which contributes adversely to patient outcome, given that accurate diagnosis facilitates earlier treatment of this curable disease. This article will address relevant imaging aspects, with reference to typical and atypical imaging features of CD, illustrated using examples from our specialist centre; the imaging journey for patients with CD; and will provide practical pointers to radiologists in differentiating CD from other benign and malignant causes of enhancing lymphadenopathy, including lymphoma and neoplastic adenopathy. We will also review current classification tools and staging challenges with reference to World Health Organization guidelines, International Working Group guidelines as well as the Lugano classification. Finally, we will discuss the potential role of additional im-aging techniques in CD, highlighting novel imaging methods and expanded utilities from our specialist centre. Crown Copyright ?? 2022 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved.
引用
收藏
页码:399 / 408
页数:10
相关论文
共 30 条
[1]  
[Anonymous], 2016, PHARMACOECON OUTCOME, V746, DOI [10.1007/s40274-016-2786-x.8-8, DOI 10.1007/S40274-016-2786-X.8-8]
[2]   FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease [J].
Barker, Rob ;
Kazmi, Fahrad ;
Stebbing, Justin ;
Ngan, Sarah ;
Chinn, Roger ;
Nelson, Mark ;
O'Doherty, Michael ;
Bower, Mark .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (04) :648-652
[3]   Castleman Disease: The Great Mimic [J].
Bonekamp, David ;
Horton, Karen M. ;
Hruban, Ralph H. ;
Fishman, Elliot K. .
RADIOGRAPHICS, 2011, 31 (06) :1793-1807
[4]   The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care [J].
Casper, C .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :3-17
[5]   Update and new approaches in the treatment of Castleman disease [J].
Chan, Kah-Lok ;
Lade, Stephen ;
Prince, H. Miles ;
Harrison, Simon J. .
JOURNAL OF BLOOD MEDICINE, 2016, 7 :145-158
[6]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[7]   Castleman Disease An Update on Classification and the Spectrum of Associated Lesions [J].
Cronin, Danielle M. P. ;
Warnke, Roger A. .
ADVANCES IN ANATOMIC PATHOLOGY, 2009, 16 (04) :236-246
[8]   Evolution of lymphoma staging and response evaluation: current limitations and future directions [J].
Cunningham, Joel ;
Iyengar, Sunil ;
Sharma, Bhupinder .
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (10) :631-645
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics [J].
El-Osta, Hazem E. ;
Kurzrock, Razelle .
ONCOLOGIST, 2011, 16 (04) :497-511